



Casirivimab and Imdevimab Added as Texas Medicaid Benefit

What is New?

On December 15, 2020, Texas Medicaid added casirivimab and imdevimab as a benefit in response to the COVID-19 Emergency Use Authorization (EUA). As of November 21, 2020, the drug is allowed as a covered benefit. Below is billing information and requirements.

Procedure Code	Administration Code
Q0243 – casirivimab and imdevimab	M0243 – Administration of casirivimab and imdevimab

Requirements for Billing:

- **Place of service:** Outpatient
- **Diagnosis Code:** U07.1 (mild to moderate COVID-19)
- **Ages** 12 year old and up
- **Weight:** at least 40kg
- **Status:** High risk of progressing to severe COVID-19 or requiring hospitalization
- **What’s reimbursed:** The federal government is currently purchasing casirivimab and imdevimab. It's providing casirivimab and imdevimab to states to distribute to health care providers at no cost for COVID-19 treatment. **We won't reimburse for casirivimab and imdevimab that providers received for free.** Providers should not charge members for the treatment. We will **reimburse for the administration of the treatment.** Other medically necessary treatment for COVID-19 will be covered consistent with the terms of the member's benefit plan. When providers begin to purchase casirivimab and imdevimab, we will update our position.

Have questions:

Contact our BCBSTX Medicaid Provider Service Center at 1-877-560-8055 or contact your BCBSTX Medicaid Provider Network Representative at 1-855-212-1615.